Matching articles for "opioid use disorder"
Issue 1726 · April 14, 2025 Free
In Brief: New Labeling for Once-Monthly Subcutaneous Buprenorphine (Sublocade)

The FDA has approved changes to the labeling of Sublocade (Indivior), an extended-release formulation of the partial opioid agonist buprenorphine, to permit faster initiation and use of alternative injection…

Med Lett Drugs Ther. 2025 Apr 14; 67(1726):63-4 doi:10.58347/tml.2025.1726e
The FDA has approved changes to the labeling of Sublocade (Indivior), an extended-release formulation of the partial opioid agonist buprenorphine, to permit faster initiation and use of alternative injection sites. Sublocade is indicated for once-monthly subcutaneous treatment of moderate to severe opioid use disorder.
Issue 1698 · March 18, 2024 Free
In Brief: A New OTC Naloxone Nasal Spray (RiVive)

The FDA has approved RiVive (Harm Reduction Therapeutics), a 3-mg naloxone nasal spray, as an over-the-counter (OTC) product for emergency treatment of opioid overdose. Two 4-mg naloxone nasal spray…

Med Lett Drugs Ther. 2024 Mar 18; 66(1698):47-8 doi:10.58347/tml.2024.1698d
The FDA has approved RiVive (Harm Reduction Therapeutics), a 3-mg naloxone nasal spray, as an over-the-counter (OTC) product for emergency treatment of opioid overdose. Two 4-mg naloxone nasal spray formulations, Narcan and one of its generics, were approved for OTC sale in 2023.
Issue 1687 · October 16, 2023
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose

The FDA has approved an intranasal formulation of the opioid antagonist nalmefene ( Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene,…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):166-7 doi:10.58347/tml.2023.1687b
The FDA has approved an intranasal formulation of the opioid antagonist nalmefene ( Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene, which is available by prescription, is the second opioid antagonist to become available as a nasal spray for this indication; the first was naloxone, which is now available for sale over the counter ( Narcan , and generic). Other nasal spray formulations of naloxone and injectable formulations of nalmefene and naloxone are available by prescription (see Table 2).
Issue 1686 · October 2, 2023 Free
Addendum: Over-the-Counter Narcan Nasal Spray

Since the publication of our articles entitled Drugs for Opioid Use Disorder and In Brief: Over-the-Counter Narcan Nasal Spray earlier this year, Narcan (Emergent), a nasal spray that delivers 4 mg of the…

Med Lett Drugs Ther. 2023 Oct 2; 65(1686):160 doi:10.58347/tml.2023.1686f
Since the publication of our articles entitled Drugs for Opioid Use Disorder and In Brief: Over-the-Counter Narcan Nasal Spray earlier this year, Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone, has become available for sale over the counter (OTC). According to the manufacturer, the retail price for a box containing 2 doses is $44.99. Some insurance companies have announced plans to cover OTC purchase of the drug for their members.
Issue 1684 · September 4, 2023 Free
Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)

View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder

Med Lett Drugs Ther. 2023 Sep 4; 65(1684):e144-5 doi:10.58347/tml.2023.1684b
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Issue 1684 · September 4, 2023 Free
Drugs for Opioid Use Disorder

Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections…

Med Lett Drugs Ther. 2023 Sep 4; 65(1684):137-44 doi:10.58347/tml.2023.1684a
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Issue 1683 · August 21, 2023
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder

The FDA has approved a subcutaneously injected, extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine ( Brixadi – Braeburn) for once-weekly…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):133-5 doi:10.58347/tml.2023.1683c
The FDA has approved a subcutaneously injected, extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine ( Brixadi – Braeburn) for once-weekly or once-monthly treatment of moderate to severe opioid use disorder. Brixadi is the second subcutaneously injected buprenorphine formulation to be approved in the US; Sublocade , which is administered once monthly, was the first. Buprenorphine is also available for treatment of opioid use disorder in sublingual formulations with and without the opioid antagonist naloxone.